Prater, S. & McKeon, B. in StatPearls (StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC., 2024).
Du, X. et al. Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities. Front. Oncol. 13, 1117867 (2023).
Xu, Y. et al. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors. Int. J. Cancer 154, 226–240 (2024).
Li, S., Zhang, H., Liu, J. & Shang, G. Targeted therapy for osteosarcoma: a review. J. Cancer Res. Clin. Oncol. 149, 6785–6797 (2023).
Wang, S. et al. The Targeted Therapies for Osteosarcoma via Six Major Pathways. Curr. Mol. Pharmacol. 17, e210823220109 (2024).
Kotb, M. et al. Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends Genet 13, 51–52 (1997).
Lu, S. C. & Mato, J. M. Role of methionine adenosyltransferase and S-adenosylmethionine in alcohol-associated liver cancer. Alcohol 35, 227–234 (2005).
Bottiglieri, T. S-Adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotrophic molecule. Am. J. Clin. Nutr. 76, 1151S–1157S (2002).
Timp, W. & Feinberg, A. P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer 13, 497–510 (2013).
Cai, J., Sun, W. M., Hwang, J. J., Stain, S. C. & Lu, S. C. Changes in S-adenosylmethionine synthetase in human liver cancer: molecular characterization and significance. Hepatology 24, 1090–1097 (1996).
Simile, M. M. et al. MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes. Oncotarget 10, 2835–2854 (2019).
Xu, J., Wu, D., Wang, S. & Wang, Z. MAT2B expression correlates with poor prognosis in triple-negative breast cancer. Cancer Manag Res 11, 5501–5511 (2019).
Zhang, Y. et al. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer. J. Immunother. Cancer 9, https://doi.org/10.1136/jitc-2020-001364(2021).
Chen, Y. W. et al. Circ_0044516 Regulates miR-136/MAT2A Pathway to Facilitate Lung Cancer Development. J. Immunol. Res 2021, 5510869 (2021).
Wang, L. et al. SYVN1-MTR4-MAT2A Signaling Axis Regulates Methionine Metabolism in Glioma Cells. Front Cell Dev. Biol. 9, 633259 (2021).
Yang, C. et al. Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment. Cell Death Dis. 14, 525 (2023).
Wang, Y. et al. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma. Haematologica 109, 256–271 (2024).
Xia, S., Liang, Y., Shen, Y., Zhong, W. & Ma, Y. MAT2A inhibits the ferroptosis in osteosarcoma progression regulated by miR-26b-5p. J. Bone Oncol. 41, 100490 (2023).
Deng, B., Deng, J., Yi, X., Zou, Y. & Li, C. ROCK2 Promotes Osteosarcoma Growth and Glycolysis by Up-Regulating HKII via Phospho-PI3K/AKT Signalling. Cancer Manag. Res. 13, 449–462 (2021).
Wang, J. & Schwartz, R. J. Sumoylation and regulation of cardiac gene expression. Circ. Res 107, 19–29 (2010).
Patyal, P. et al. Rho/SRF Inhibitor Modulates Mitochondrial Functions. Int. J. Mol. Sci. 23, https://doi.org/10.3390/ijms231911536 (2022).
Li, J. et al. Signalosome-Regulated Serum Response Factor Phosphorylation Determining Myocyte Growth in Width Versus Length as a Therapeutic Target for Heart Failure. Circulation 142, 2138–2154 (2020).
Li, K. et al. The SUMOylation and ubiquitination crosstalk in cancer. J. Cancer Res Clin. Oncol. 149, 16123–16146 (2023).
Han, Z. J., Feng, Y. H., Gu, B. H., Li, Y. M. & Chen, H. The post-translational modification, SUMOylation, and cancer (Review). Int J. Oncol. 52, 1081–1094 (2018).
Li, C. et al. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors. J. Medicinal Chem. 65, 9531–9547 (2022).
Cevher, M. A. et al. Nuclear deadenylation/polyadenylation factors regulate 3’ processing in response to DNA damage. EMBO J. 29, 1674–1687 (2010).
Devany, E., Zhang, X., Park, J. Y., Tian, B. & Kleiman, F. E. Positive and negative feedback loops in the p53 and mRNA 3’ processing pathways. Proc. Natl. Acad. Sci. USA 110, 3351–3356 (2013).
Gherzi, R. et al. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol. Cell 14, 571–583 (2004).
Zhang, F. W. et al. Poly(A)-specific ribonuclease protein promotes the proliferation, invasion and migration of esophageal cancer cells. World J. Gastroenterol. 29, 4783–4796 (2023).
Nanjappa, D. P. et al. Poly (A)-specific ribonuclease (PARN): More than just “mRNA stock clearing. Life Sci. 285, 119953 (2021).
Yin, J. et al. Cross-talk between PARN and EGFR-STAT3 Signaling Facilitates Self-Renewal and Proliferation of Glioblastoma Stem Cells. Cancer Res. 83, 3693–3709 (2023).
Li, J. T. et al. Dietary folate drives methionine metabolism to promote cancer development by stabilizing MAT IIA. Signal Transduct. Target Ther. 7, 192 (2022).
Li, F. et al. Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer. Nat. Cancer 5, 131–146 (2024).
Zhang, S. et al. Design and Structural Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High In Vivo Potency and Oral Bioavailability. J. Med Chem. 66, 4849–4867 (2023).
Hung, M. H. et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat. Commun. 12, 1455 (2021).
Jiang, N. et al. Role of PI3K/AKT pathway in cancer: the framework of malignant behavior. Mol. Biol. Rep. 47, 4587–4629 (2020).
Abbaszadeh, Z., Cesmeli, S. & Biray Avci, C. Crucial players in glycolysis: Cancer progress. Gene 726, 144158 (2020).
Kamyab-Hesary, K., Ghanadan, A., Balighi, K., Mousavinia, S. F. & Nasimi, M. Immunohistochemical Staining in the Assessment of Melanoma Tumor Thickness. Pathol. Oncol. Res 26, 885–891 (2020).
Sule, R., Rivera, G. & Gomes, A. V. Western blotting (immunoblotting): history, theory, uses, protocol and problems. BioTechniques 75, 99–114 (2023).